Berobenatide

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

ObesityOverweight And/or Obesity

176 competitors in Obesity

#DrugCompanyPhaseTrials

1

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

12

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

13

NNC0487-0111

Novo Nordisk

Phase 3

114

Berobenatide

Pfizer

Phase 3

55

Survodutide

Boehringer Ingelheim

Phase 3

26

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

17

Actemra

Roche

Preclinical

28

Avapro

Sanofi

Preclinical

19

Amidate

Pfizer

Preclinical

—10

Calciferol

Jazz Pharmaceuticals

Preclinical

—Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity5 trials

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY PF-08653944 IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY

Recruiting·Pfizer·Phase 3·NCT07792954·300 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JW)

Recruiting·Pfizer·Phase 3·NCT07794761·180 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF 08653944 IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY

Not yet recruiting·Pfizer·Phase 3·NCT07874633·432 enrolled

Show 2 more trials

A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)

Recruiting·Pfizer·Phase 3·NCT07845500·660 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JM)

Not yet recruiting·Pfizer·Phase 3·NCT07794774·197 enrolled

Apnea2 trials

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY NOT RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 2)

Not yet recruiting·Pfizer·Phase 3·NCT07881757·258 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)

Recruiting·Pfizer·Phase 3·NCT07823608·258 enrolled

Overweight and/or Obesity1 trial

PHASE 1, SINGLE DOSE, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, PK COMPARABILITY STUDY BETWEEN DIFFERENT DELIVERY SYSTEMS OF BEROBENATIDE IN ADULTS WITH OVERWEIGHT OR OBESITY

Not yet recruiting·Pfizer·Phase 1·NCT07876531·144 enrolled

Details

Drug Info

Related News